Eli Lilly LLY is a dominant player in the cardiometabolic space, all thanks to the encouraging uptake for its blockbuster GLP ...

Eli Lilly's Mounjaro clocked in ₹80 crore in September, second only to India’s leading brand of the month, GSK’s Augmentin, ...

What is the ‘golden dose’ and what are the risks? Medical News Today asks four experts to weigh in on the trend of trying to ...

In January, when Sarah le Brocq signed up for a year’s supply of weight loss jab Mounjaro at £99 per month, it felt like a ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand ...

Shares of Novo Nordisk and Eli Lilly dropped sharply in early trading Friday after President Donald Trump said Thursday that ...

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...